Canadian Cancer Trials Group Bulletins

General


PA.6 and Pancreatic Cancer Canada

The Canadian Cancer Trials Group and Pancreatic Cancer Canada have teamed up to promote awareness of Canadian Cancer Trials Group PA.6 - A Multicentre Randomized Phase III Trial Comparing 6-Month Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) In Patients With Resected Pancreatic Adenocarcinoma.

PA.6 is an exciting clinical trial that is currently enrolling patients who have completed their surgery for pancreatic cancer. The purpose of the study is to compare gemcitabine to a new chemotherapy treatment called FOLFIRINOX that researchers believe may provide a higher chance of cure. This study is being done to determine whether FOLFIRINOX is more effective than gemcitabine in prolonging survival, and whether FOLFIRINOX is a safe and tolerable treatment.

PA.6 is recruiting participants from France and Canada, and we are hoping to increase awareness of the study to encourage patients to participate.

The Canadian Cancer Trials Group is grateful to Pancreatic Cancer Canada for promoting this trial!!

For the complete article, please use this link ... http://www.pancreaticcancercanada.ca/site/PageServer?pagename=research_clinical_trial.

If you have questions or would like more information about PA.6, please contact Barbara Graham, Study Coordinator, at (613) 533-6430 or bgraham@ctg.queensu.ca.